Nektar Therapeutics Q2 Loss increases, but beats estimates

(RTTNews) - Nektar Therapeutics (NKTR) released Loss for its second quarter that increased from last year but beat the Street estimates.

The company's earnings came in at -$159.07 million, or -$0.85 per share. This compares with -$125.52 million, or -$0.69 per share, in last year's second quarter.

Analysts on average had expected the company to earn -$0.94 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.

The company's revenue for the quarter fell 23.8% to $21.59 million from $28.33 million last year.

Nektar Therapeutics earnings at a glance (GAAP) :

-Earnings (Q2): -$159.07 Mln. vs. -$125.52 Mln. last year. -EPS (Q2): -$0.85 vs. -$0.69 last year. -Analyst Estimate: -$0.94 -Revenue (Q2): $21.59 Mln vs. $28.33 Mln last year.